One-year resource utilisation, costs and quality of life in patients with acute respiratory distress syndrome (ARDS): Secondary analysis of a randomised controlled trial by Marti, J et al.
RESEARCH Open Access
One-year resource utilisation, costs and
quality of life in patients with acute
respiratory distress syndrome (ARDS):
secondary analysis of a randomised
controlled trial
Joachim Marti1*, Peter Hall2, Patrick Hamilton3, Sarah Lamb4, Chris McCabe5, Ranjit Lall6, Julie Darbyshire7,
Duncan Young7 and Claire Hulme8
Abstract
Background: The long-term economic and quality-of-life outcomes of patients admitted to intensive care unit
(ICU) with acute respiratory distress syndrome are not well understood. In this study, we investigate 1-year costs,
survival and quality of life following ICU admission in patients who required mechanical ventilation for acute
respiratory distress syndrome.
Methods: Economic analysis of data collected alongside a UK-based multi-centre randomised, controlled trial,
aimed at comparing high-frequency oscillatory ventilation with conventional mechanical ventilation. The study
included 795 critically ill patients admitted to ICU. Hospital costs were assessed using daily data. Post-hospital
healthcare costs, patient out-of-pocket expenses, lost earnings of survivors and their carers and health-related
quality of life were assessed using follow-up surveys.
Results: The mean cost of initial ICU stay was £26,857 (95 % CI £25,222–£28,491), and the average daily cost in ICU
was £1738 (CI £1667–£1810). Following hospital discharge, the average 1-year cost among survivors was £7523 (CI
£5692–£9354). The mean societal cost at 1 year was £44,077 (£41,168–£46,985), and the total societal cost divided
by the number of 1-year survivors was £90,206. Survivors reported significantly lower health-related quality of life
than the age- and sex-matched reference population, and this difference was more marked in younger patients.
Conclusions: Given the high costs and low health-related quality of life identified, there is significant scope for
further research aimed at improving care in this in-need patient group.
Trial registration: ISRCTN10416500
Background
Intensive care units (ICU) account for an important
share of hospital budgets for a relatively small volume of
patients given the complex procedures involved, the use
of costly technology and medications, and the involve-
ment of highly qualified staff. Patients admitted to ICU
with acute respiratory distress syndrome (ARDS), an
inflammatory lung condition, are particularly resource-
intensive [1–3], have high mortality and morbidity [4–
8], and survivors report lower quality of life than other
critically ill patients [9]. Patients with ARDS often re-
quire mechanical ventilation (MV), a particularly costly
life-sustaining therapy [2]. As MV itself can cause lung
injury, inflammation and even death [10], alternative
ventilation strategies that better protect the lungs have
been called for. Recent large trials have examined the
effectiveness of high-frequency oscillatory ventilation
(HFOV) as compared to conventional ventilation in
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patients with ARDS but have not demonstrated any im-
provement in short-term mortality with the use of
HFOV [11, 12]. A comprehensive evaluation of these al-
ternative therapies requires the assessment of long-term
mortality outcomes and the consideration of resource
use and patient quality of life [13–17]. The volume of
high quality data arising from recent research in this
area presents new opportunities for knowledge gener-
ation beyond the core objectives of those studies.
Following discharge, recovery is challenging for survi-
vors of ARDS as physical and neuropsychological dis-
abilities may persist for years [6, 17–23]. In the long run,
health-related quality of life (HRQL) of the survivors of
ARDS and other critically ill patients has been found to
be significantly lower than for the general population [1,
9, 24–32]. To date, economic studies of patients with
ARDS mostly focused on ICU and hospital costs [3, 33,
34] and few studies have examined the long-term costs
among ICU survivors [31, 35, 36]. Survivors of ARDS
may require on-going treatments and rehabilitation fol-
lowing hospital discharge [1, 19, 26] as well as extensive
support from carers [6], which may lead to an important
economic cost to the health sector and the society as a
whole [35, 37]. The measurement and reporting of costs
and quality-adjusted life years (QALYs) in ICU popula-
tions is vital to allow health service and policy advances.
In this paper, we used in-hospital trial data and follow-
up questionnaires of a prospective cohort of patients
with ARDS to examine 1-year healthcare utilisation and
quality-of-life outcomes, enabling the calculation of
costs and QALYs. The economic and quality-of-life data
were collected alongside the OSCAR trial [12], a
multi-centre randomised, controlled trial of HFOV as
compared with conventional mechanical ventilation, con-
ducted in England, Wales and Scotland. We assessed the
economic costs and benefits within the initial year follow-
ing randomisation and estimated detailed costs for various
parts of the care pathway (initial ICU stay, hospital stay
following first ICU discharge and post-hospital resource
use) and patient groups.
Methods
Patient population
The data used in this study come from the OSCAR
study, a multi-centre, randomised, controlled trial of
HFOV as compared to conventional MV in patients with
moderate-to-severe ARDS. Patients (>16 years) who
were undergoing MV were recruited in different-sized
ICUs from 29 hospitals across England, Wales and
Scotland and were randomised to either HFOV or con-
ventional MV. Patients were eligible if they were ex-
pected to require at least two more days of MV and met
the definition of moderate or severe ARDS. Patients
were excluded if they had been on ventilation for 7 days
or more. Inclusion criteria for OSCAR and patient re-
cruitment have been described in detail in Young et al.
[12]. The study was approved by national ethics review
committees and research governance departments at
each centre. Patients or their representatives provided
written informed consent.
Data collection
Characteristics such as age, gender, ventilation prior to
enrolment, physiology and other information required to
assess illness severity were collected at the time of ran-
domisation. The Acute Physiology, Age, and Chronic
Health Evaluation (APACHE II) score was used to meas-
ure the severity of illness within the first 24 h after the
patient was admitted to an ICU. The APACHE II score
is based on several physiological measurements and pre-
admission health status and ranges from 0 to 71, with
higher scores corresponding to more severe illness. The
baseline ratio of the partial pressure of arterial oxygen
(PaO2) to the fraction of inspired oxygen (FiO2) was
also recorded as a measure of the severity of ARDS.
Case report forms (CRFs) were completed by the med-
ical and nursing staff for each day a patient was in ICU.
The CRFs recorded the use of antibiotics, sedatives and
muscle relaxant drugs as well as information on support
for organ systems. Serious adverse events and whether
the patient required a chest drain or presented radio-
logical evidence of barotrauma were also recorded. ICU
discharge date and location, ICU readmissions and hos-
pital discharge date were available.
Following hospital discharge, questionnaires were sent
to surviving patients and their carers at 6 and 12 months.
Patients were asked about their use of medical services
during the previous 6 months, including primary- and
community-based health and social services and residen-
tial inpatient stays. The questionnaires also contained
questions related to the use of aids and equipment, gross
loss of earnings and other major expenses. Patients’
questionnaires also recorded quality of life using the
EuroQol-5D (EQ-5D) [38]. Carers’ questionnaires re-
corded the cost of travel to and from medical services,
major expenses and loss of earnings.
Data analysis
Quality of life
Patients’ HRQL was measured at 6 and 12 months using
EQ-5D. Health utility weights for each patient were
derived from EQ-5D responses using the standard UK
specific tariffs [39]. For each time period, mean utility
scores were compared to those of an age- and sex-
matched reference population [39].
To obtain mean QALYs at 1 year, quality of life and
survival data were combined into a single metric. Pa-
tients’ histories were partitioned into several periods
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from randomisation to 1 year, and a utility value was
assigned to each of these periods [40]. For the ventila-
tion period, we multiplied the average number of days
ventilated by the utility weight of an unconscious patient
reported in the EQ-5D scoring manual (−0.4) [38]. We
then calculated the mean utility scores of survivors at 6
and 12 months using all available questionnaires and, as-
suming a linear change in HRQL between assessments,
we calculated mean utility scores at two additional mid-
points (3 and 9 months). The mean time in each period
was obtained by calculating the area under the relevant
Kaplan-Meier survival curve. The sum of the mean sur-
vival time in each state multiplied by the utility weights
provided an estimate of the quality-adjusted survival at
1 year, expressed in QALYs.
Costing methodology
We used a bottom-up micro-costing approach where we
assigned unit costs to volumes of resource use for each
patient [41]. We analysed costs from the perspective of
the health and social care sector (NHS) and from a
broader societal perspective. Costing was undertaken for
the various pathways of care following ICU admission:
initial ICU stay, hospital stay following first ICU dis-
charge, post-hospital NHS resource use and societal
costs. ICU and hospital costs were assessed using the
bottom-up approach [36, 42, 43].
Resource use associated with initial stay in ICU was
assessed daily based on the number of organs supported,
respiratory support, whether the patient was on renal re-
placement therapy, whether he/she required X-rays (to
check for barotrauma) or a chest drain (pneumothorax)
and use of medicines. The quantities of resource use
were multiplied by their corresponding unit costs, and
the sum per patient for the entire stay was calculated.
The unit costs of ICU resources including cost per organ
supported, radiology and the cost of pneumothorax were
taken from the National Schedule of Reference Costs
[44]. The costs of medicines used were taken from the
British National Formulary (BNF) [45]. The daily cost of
ventilation was based on a fixed and per patient cost.
We assumed that ventilation machines would be used
for 5 years; annual maintenance and the costs of single
use circuits were also included.
Once patients were discharged from ICU, the cost of
step-down and the cost of ICU readmissions were calcu-
lated using the number of days until death or discharge
multiplied by the cost of the level of care required, based
on various nationally available references [44, 46, 47]. If
a patient was discharged to another hospital following
ICU, the cost of transport was taken as that of an emer-
gency transfer. Serious adverse events and corresponding
unit costs were assessed on an individual basis. Patient-
reported data on resource use were collected at 6 and
12 months. NHS resource use included further inpatient
care, outpatient care, primary- and community-based
care and aids and equipment provided by the NHS. The
costs of attendance at medical services were calculated
using national reference costs multiplied by the number
of times a patient attended [44, 47]. Inpatient stays were
based on the number of days admitted multiplied by the
corresponding unit cost [47]. The cost of aids and equip-
ment was taken from the NHS supply chain cost for
each individual item. Costs incurred by patients and
their carers included cost of travel, loss of earnings and
patient out-of-pocket expenses for aids, equipment and
extra expenses (home adaptations). The cost of travel to
and from appointments for both carers and patients was
based on the distance in miles provided in the question-
naires multiplied by the cost per petrol mile as provided
by HM Revenue & Customs (HMRC) [48]. Patients and
carers were asked to give the gross amount lost in earn-
ings in the 6 months covered by each questionnaire.
Cost of aids and equipment purchased by patients was
directly reported in the patient questionnaire. All costs
were adjusted to 2012 prices using the Hospital and
Community Healthcare Services (HCHS) index pub-
lished by the Personal Social Services Research Unit
(PSSRU) [47]. Unit costs used in the analysis and more
details on the costing strategy are provided in the sup-
plemental appendix.
Outcomes
The primary outcomes were 1-year survival, quality of
life and resource use. Resource use was measured in
terms of duration of treatment in both the ICU and the
hospital and in terms of health care and societal costs at
1 year, divided into the various care pathways, i.e. ICU
stay, hospital stay and post-discharge period. These out-
comes were presented for various subgroups of patients
based on baseline demographic, physiological, and clin-
ical characteristic, including ventilation strategy (HFOV
or conventional ventilation). Total cost per 1-year sur-
vivor was obtained by dividing the sum of ICU, hospital,
and post-hospital costs for all patients by the number of
patients remaining alive 1 year post-randomisation. The
1-year incremental cost effectiveness ratio (ICER) of
HFOV as compared to conventional MV was also calcu-
lated. The ICER was obtained by dividing the difference
between the average 1-year costs in the HFOV group,
and the average 1-year cost in the conventional ventila-
tion group by the difference between average health out-
comes (QALYs) gained in the HFOV group and those
gained in the conventional ventilation group [49].
Statistical analyses
Patient characteristics are presented using means and
standard deviations (SD) for continuous variables and
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proportions and percentages for categorical variables.
We compared baseline characteristics of 1-year survivors
and non-survivors using Student’s t tests for continuous
variables and chi-squared tests for categorical variables.
No corrections were made for multiple testing. Cost data
are presented using means, 95 % confidence intervals,
median and interquartile range. HRQL at 6 and
12 months and quality-adjusted survival were sum-
marised using means and 95 % confidence intervals.
HRQL of survivors was compared to population refer-
ence values using Student’s t tests. We first estimated
mean post-hospital costs based on complete cases. To
obtain total costs at 1-year for each patient, missing data
on post-hospital costs among 1-year survivors was ad-
dressed by multiple imputation using chained equations.
We used a truncated model in which costs were con-
strained to be equal or above zero and generated ten
datasets. Estimates from each imputed dataset were
combined following Rubin’s rule [50]. All p values were
two-sided, and a significance level of less than 0.05 was
used. R 3.0.2 and Stata 12 (Statacorp, College Station,
TX, USA) were used for the analyses.
Results
Patients
A total of 795 patients underwent randomisation. A flow
chart of the study population is presented in Fig. 1.
Among the 795 patients included in the analysis, 343 pa-
tients died in ICU and 47 died in hospital after ICU dis-
charge (in-hospital mortality rate of 49.1 %). Of the 405
remaining patients, 17 died between hospital discharge
and the 12 months follow-up. Thus, the 1-year mortality
rate was 51.2 %. A total of 234 patients completed the
cost and quality-of-life questionnaires at 6 months, and
205 patients completed the questionnaires at 12 months
(response rate of 58.9 and 52.8 %, respectively). Overall,
170 1-year survivors and 95 carers completed both the
6-month and the 12-month questionnaires. Baseline pa-
tient characteristics are displayed in Table 1. The mean
age was 55 years and most patients were male (62.3 %)
and had pneumonia identified as the primary cause of
ARDS (58.6 %). The mean ICU length of stay (+/− SD)
was 17.0+/−16.5 days, and the mean hospital length of
stay was 33.6+/−43.1 days. Compared to 1-year survi-
vors, non-survivors were older, had a higher APACHE
II score, lower PaO2:FiO2 ratio and were less likely to
have been admitted in surgery. 1-year survivors who
have completed both 6 and 12 months questionnaires
were younger and had lower APACHE II scores than
1-year survivors with incomplete information (unre-
ported analysis).
Survival and quality of life
Figure 2 shows the Kaplan-Meier survival estimates at
1 year by age, APACHE II score and ventilation strategy
(HFOV and conventional ventilation), based on complete
follow-up data on mortality. Higher 1-year mortality was
observed among older (≥ 65) patients (OR 3.98, 95 % CI
2.86–5.55) and patients with higher (>26) APACHE II
score (OR 2.55, 95 % CI 1.80–3.63), after adjustment for
Fig. 1 Flow chart of study population
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sex and PaO2:FiO2 ratio by logistic regression. The shape
of the Kaplan-Meier curve suggests that the largest
differences in mortality rates between these groups are
observed within the first 30 days from randomisation
and that, after 60 days, mortality rates were relatively
low and stable in all groups. There was no significant
difference in 1-year survival in the HFOV group as com-
pared to the conventional ventilation group (OR 1.06,
95 % CI 0.79–1.43).
Health-related quality of life of survivors in the dif-
ferent age groups and for an age- and sex-matched
population of reference is displayed in Table 2, separ-
ately for the 6 and 12 months follow-up. Survivors of
ARDS reported significantly lower HRQL than the
age- and sex-matched reference population and this
difference was more marked in younger (<65 years)
patients. Table 3 displays HRQL data at 6 and
12 months in various patient groups. Combining the
survival and HRQL information, we obtained a mean
quality-adjusted survival at 1 year of 0.27 (0.25–0.29),
indicating that for every 100 patients admitted in
ICU, 27 QALYs were generated over a 1-year period.
Mean QALY over the period was significantly lower
for older (≥65) patients and patients with higher
(>26) APACHE II score, and higher in the HFOV
group, as compared to the conventional ventilation
group.
Costs
As shown in Table 4, the mean per-patient cost of initial
ICU stay among patients with ARDS was £26,857 (95 %
CI £25,222–£28,491) and the average cost per day in
ICU was £1738 (95 % CI £1667–£1810). Following initial
ICU discharge, the mean cost of hospital stay among
ICU survivors was £19,195 (95 % CI £15,936–£22,455)
at an average daily cost of £732 (95 % CI £643–£821).
Overall, a patient admitted to ICU with ARDS had an
expected hospital cost of £37,626 (95 % CI £34,866–
£40,385), and the average daily cost of the hospital stay
was £1446 (95 % CI £1406–£1486). Following hospital
discharge, the average 1-year cost amongst survivors was
£7523 (95 % CI £5692–£9354). This comprised costs to
the NHS (£3935), including primary and community-
based care, hospital and residential stays and equipment
and aids paid by the NHS, and costs to the patient and
their carers (£3556), including travel costs to and from
appointments, earning losses and extra expenses. These
estimates were based on complete case analysis. The
average 1-year post-hospital cost using multiple imputed
data was £6624 (95 % CI £4464–£8784). The mean
societal (total) cost at 1 year was £44,077 (95 % CI
£41,168–£46,985), and the total societal cost divided by
the number of 1-year survivor was £90,206 (this repre-
sents the mean 1 year cost of a survivor).
In-hospital resource use in patient subgroups is dis-
played in Table 5. Although HFOV patients had higher
1-year costs as compared to conventional ventilation
patients, the difference was not statistically significant.
1-year survivors with APACHE II score over 22 exhib-
ited higher ICU and hospital costs and had longer hos-
pital stays than less severely ill patients. Overall, the cost
of initial ICU stay accounted for 70 % of total hospital
costs. As expected, healthcare costs were skewed and ex-
hibited high between-patient variation. We identified 10
patients with extreme (>£200,000) societal costs. These
patients were relatively young on average (mean 50 years)
and had long hospital stays (mean 193 days).
Discussion
In this multicentre study conducted in 29 hospitals across
England, we found that adults admitted to ICU with
moderate-to-severe ARDS had high 1-year mortality
(51.8 %) and incurred high hospital costs (mean = £37,626;
CI £34,866–£40,385). Our results are comparable to those
obtained in a multi-country study where the reported
daily ICU costs ranged from €1168 to €2025 [51]. How-
ever, previous ICU costing studies gave rise to a wide
range of daily ICU cost estimates [51, 52], [53] due to an
Table 1 Baseline patient characteristics
Characteristic All patients (N = 795) 1-year survivors (N = 388) 1-year non-survivors (N = 407) P value
Age—years [SD] 55.4 [16.8] 50.2 [15.6] 60.4 [16.4] <0.001
Female—no. (%) 300 (37.7) 148 (38.1) 152 (37.4) 0.8168
APACHE II score [SD]a 21.8 [6.1] 20.3 [5.7] 23.2 [6.0] <0.001
PaO2:FiO2 ratio—KPa [SD] 15.1 [5.0] 16.0 [5.2] 14.2 [4.6] <0.001
Prime condition: Pneumonia/pneumonitis—no. (%) 466 (58.6) 220 (56.7) 246 (60.4) 0.2849
Surgery admission—no. (%) 108 (13.6) 64 (16.5) 44 (10.8) 0.0194
ICU length of stay—days [SD] 17.0 [16.5] 19.7 [15.5] 14.4 [16.9] <0.001
Hospital length of stay—days [SD]b 33.6 [43.1] 47.2 [48.6] 20.9 [32.3] <0.001
APACHE Acute Physiology and Chronic Health Evaluation, FiO2 fraction of inspired oxygen and PaO2 partial pressure of arterial oxygen
aAPACHE II score calculated for 765 patients only
bFive patients with missing information on hospital discharge
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important variation in methodological approaches and
underlying assumptions. Analyses among survivors re-
vealed lower than normal quality of life and non-
negligible resource use and costs following hospital
discharge. These were equally split between health and
social care costs (mean = £3935; CI £2917–£4953) and
costs to the patient and their carers (mean = £3556; CI
£2332–£4780). The cost per 1-year survivor was £90,206
(CI £84,536–£96,134), which is higher than figures previ-
ously published in ARDS patients [1] possibly due to
Fig. 2 Kaplan-Meier survival plots at 12 months
Table 2 HRQL of ARDS patients at 6 and 12 months, compared with age- and sex-matched reference values
ARDS patients Age- and sex-matched reference values P value
Mean (SD) Mean (SD)
EQ5D index at 6 months
Patients under 65 0.55 (0.37) 0.85 (0.06) <0.001
Patients 65 and above 0.62 (0.37) 0.77 (0.02) 0.003
EQ5D at 12 months
Patients under 65 0.58 (0.35) 0.85 (0.06) <0.001
Patients 65 and above 0.58 (0.38) 0.77 (0.02) <0.001
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Table 3 Quality of life
6 months 12 months Quality-adjusted survival at 12 months
Mean EQ5D index (95 % CI) Mean EQ5D index (95 % CI) Mean QALY (95 % CI)
All patients 0.5622 (0.5163–0.6081) 0.5831 (0.5348–0.6314) 0.2676 (0.2457–0.2894)
Age
<65 0.55 (0.49–0.60) 0.58 (0.53-0.64) 0.31 (0.28-0.35)
≥65 0.62 (0.52–0.71) 0.58 (0.48–0.68) 0.16 (0.12–0.21)
Gender
Male 0.57 (0.51–0.63) 0.58 (0.52–0.64) 0.27 (0.23–0.30)
Female 0.55 (0.47–0.63) 0.59 (0.51–0.67) 0.27 (0.23–0.31)
APACHE II
<26 0.57 (0.52–0.62) 0.57 (0.52–0.63) 0.29 (0.26–0.33)
≥26 0.48 (0.34–0.61) 0.60 (0.50–0.71) 0.16 (0.12–0.20)
PaO2:FiO2 ratio (KPa)
<15 0.57 (0.51–0.64) 0.58 (0.51–0.65) 0.23 (0.20–0.27)
≥15 0.55 (0.48–0.63) 0.59 (0.52–0.65) 0.31 (0.27–0.35)
Ventilation method
Conventional 0.52 (0.45–0.59) 0.55 (0.48–0.61) 0.25 (0.21–0.29)
HFOV 0.61 (0.54–0.67) 0.62 (0.55–0.69) 0.29 (0.25–0.33)
Table 4 Costs in different care pathways
Cost category N Mean (95 % CI) Median 25th Centile 75th Centile
Hospital costs
Initial ICU stay (all patients) 795
Total cost £26,857 (£25,222–£28,491) £21,067 £11,654 £34,263
Daily cost £1738 (£1667–£1810) £1607 £1494 £1760
Post-ICU (ICU survivors) 446
Total cost £19,195 (£15,936–£22,455) £7380 £2673 £20,665
Daily cost £732 (£643–£821) £297 £297 £1476
Hospital stay (all patients) 795
Total cost £37,626 (£34,866–£40,385) £25,013 £13,991 £46,802
Daily cost £1446 (£1406–£1486) £1516 £1051 £1711
Post-hospital costs (1-year survivors)
Costs to the NHSa 169 £3935 (£2917–£4953) £1676 £554 £5000
Costs to the patient and their carersb 91 £3556 (£2332–£4780) £395 0 £5411
Patient OOP expenses 169 £93 (£9.6–£176.4) £0 £0 £0
Patient lost earnings 169 £2836 (£1856–£3816) £0 £0 £2500
Carer OOP expenses 95 £565 (£305–£824) £18 £0 £270
Carer lost earnings 93 £503 (£153–£854) £0 £0 £0
Costs at 1 year (all patients)c 795 £44,077 (£41,168–£46,985) £31,533 £20,415 £53,786
Costs at 1 year (1-year survivors)c 388 £54,759 (£50,357–£59,162) £42,244 £29,170 £63,319
Cost per 1-year survivord 388 £90,206 (£84,536–£96,134)
aBased on 170 patients with questionnaires completed at both 6 and 12 months
bBased on 95 carers with questionnaires completed at both 6 and 12 months and based on 91 patients/carer questionnaires with complete information
cPost-hospital costs for patients with incomplete information at 6 months and/or 12 months were imputed
dSum of costs among all patients, divided by the number of survivors
Marti et al. Journal of Intensive Care  (2016) 4:56 Page 7 of 11
higher in-hospital mortality in our sample. These figures
will be of use to health economic modellers in the future
when evaluating ICU interventions; especially given exist-
ing evidence for the UK is scarce. Our study revealed
heterogeneity in costs across patient groups, especially re-
garding age and disease severity, but these results were
mostly driven by higher short-term mortality in older and
more severely ill patients. In line with previous studies [1,
Table 5 Resource use in subgroups of patients with ARDS (mean [SD])
All patients 1-year survivors
n ICU cost
£
ICU los
days
Hosp.
cost
£
Hosp. los
days
Total
societal
costa
£
n ICU cost
£
ICU los
days
Hosp.
cost
£
Hosp. los
days
Total
societal
costa
£
Age (years)
<65 540 28,173
[1040]
17.8
[0.72]
40,080
[1802]
35.6
[1.8]
46,882
[1817]
318 30,808
[1262]
19.9
[0.87]
47,470
[2465]
45.3
[2.50]
55,041
[2494]
≥65 255 24,070
[1381]
15.6
[1.00]
32,429
[2153]
28.6
[2.2]
38,135
[2172]
70 28,376
[2380]
19.2
[1.85]
46,175
[4023]
52.4
[4.64]
53,481
[4137]
Gender
Male 495 25,715
[969]
16.3
[0.67]
37,017
[1780]
31.9
[1.57]
43,728
[1804]
240 28,786
[1220]
18.7
[0.85]
46,603
[2719]
45.5
[2.45]
54,425
[2771]
Female 300 28,740
[1530]
18.4
[1.09]
38,630
[2315]
35.8
[2.76]
44,652
[2323]
148 32,938
[2156]
21.5
[1.54]
48,263
[3498]
48.4
[4.26]
55,302
[3517]
APACHE II
score
<26 577 27,160
[917]
17.3
[0.63]
38,740
[1634]
35,3
[1.73]
45,171
[1647]
310 30,058
[1224]
19.7
[0.87]
47,035
[2401]
46.8
[2.5]
54,520
[2423]
≥26 188 26,167
[1909]
16.7
[1.36]
34,226
[2979]
27.9
[2.65]
40,680
[3030]
59 34,338
[3282]
21.8
[2.3]
52,160
[5985]
50.54
[5.85]
59,962
[6194]
PaO2:FiO2 ratio
(KPa)
<15 433 26,271
[1209]
16.6
[0.85]
35,518
[1897]
29.5
[1.78]
41,958
[1926]
183 32,718
[1828]
20.9
[1.3]
50,357
[3255]
45.3
[2.9]
58,010
[3292]
≥15 362 27,557
[1134]
17.8
[0.79]
40,146
[2104]
38.0
[2.28]
46,611
[2110]
205 28,273
[1340]
18.7
[0.94]
44,450
[2827]
47.8
[3.3]
51,857
[2872]
Prime condition
Pneumonia 466 26,245
[1022]
16.7
[0.71]
36,356
[1874]
29.9
[1.6]
42,537
[1882]
220 29,987
[1380]
19.4
[0.95]
46,480
[3098]
41.7
[2.6]
53,629
[2921]
Other 329 27,723
[1410]
17.8
[1.0]
39,424
[2138]
38.3
[2.5]
46,257
[2174]
168 30,871
[1853]
20.1
[1.3]
48,227
[2849]
53.1
[3.8]
56,239
[2921]
Surgery admission
No 687 26,883
[892]
17.1
[0.62]
37,104
[1506]
32.0
[1.5]
43,495
[1519]
324 30,700
[1194]
19.9
[0.83]
47,135
[2406]
45.2
[2.4]
54,579
[2440]
Yes 108 26,690
[2404]
17.4
[1.7]
40,942
[4015]
42.1
[4.7]
47,779
[4065]
64 28,695
[3106]
18.9
[2.26]
47,752
[4584]
53.9
[5.61]
55,672
[4636]
Ventilation method
Conventional 397 25,606
[1110]
16.3
[0.76]
36,148
[1756]
32.5
[1.9]
42,489
[1764]
194 28,588
[1519]
18.3
[1.02]
44,343
[2499]
44.5
[2.96]
51,842
[2522]
HFOV 398 28,105
[1249]
18.0
[0.89]
39,100
[2207]
34.2
[2.1]
45,660
[2234]
194 32,151
[1639]
21.2
[1.20]
50,130
[3480]
48.7
[3.30]
57,677
[3536]
ICU los (1-year
survivors)
≤15 – – – – – – 198 – – 29,071
[1792]
28.7
[1.76]
36,330
[1826]
>15 – – – – – – 190 – – 66,166
[3468]
65.4
[3.67]
73,965
[3509]
aTotal societal costs estimates based on imputed data for patients with missing post-hospital cost
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26], we found that hospital costs accounted for the largest
share of the economic burden of ARDS at 1 year (81.6 %)
and that the length of ICU stay was the main cost driver.
However, as previously shown [17, 37], costs can still be
important following hospital discharge. Survivors required
extensive community-based and social care services,
specific aids and equipment and incurred extra expenses
related to home adaptations. In addition, indirect costs
such as lost earnings caused by employment reductions
and the economic value of support from caregivers were
non-negligible.
The 1-year mortality was 51.8 % in our sample, which
is in line with results reported in previous studies [31].
The mean health-related quality of life of 1-year survi-
vors was significantly lower than the age- and sex-
matched reference values, and the difference was
particularly marked among younger patients. When
survival and quality of life were combined in the full
sample, we found low quality-adjusted survival at 1 year.
Specifically, we found that 100 patients admitted in ICU
with ARDS are expected to accrue 27 QALYs in 1 year,
in line with previous estimates [24]. Overall, high mor-
tality combined with poor quality of life among survivors
gives rise to low benefit per patient 1 year post-ICU ad-
mission and high cost per survivor.
The data used in this study were collected alongside
the OSCAR trial of high-frequency oscillatory ventilation
(HFOV), as compared to conventional ventilation. The
clinical results of the OSCAR trial have shown no sig-
nificant effect of HFOV on 30-day mortality and showed
no short-term benefits or harm of HFOV [12]. In this
longer term economic analysis, we found no difference
in survival between the HFOV and conventional ventila-
tion group, but we found that patients in the HFOV arm
had better quality of life at 6 and 12 months and had
higher average costs. A comprehensive cost-effectiveness
analysis alongside the OSCAR trial was published else-
where and found no evidence of cost-effectiveness of
HFOV as compared to conventional ventilation [54].
Our study has several limitations that should be
noted. First, data on the use of community-based
health and social care among survivors were collected
retrospectively using self-completed questionnaires,
which may have affected the accuracy of the data due
to reporting and recall bias [55]. As is inherent with
most questionnaire-based research, our study suffered
from incomplete return of the quality-of-life and re-
source use questionnaires. Although partially miti-
gated against by multiple imputation, our results may
therefore be biased if the return rate depends on pa-
tient health status. Specifically, if missing data are
more prevalent in sicker patients, our cost estimates
are likely to be biased downwards and our quality of
life estimates upwards. Also, both costs and quality of
life estimates were based on a linearity assumption as
we had to rely on two data collection points for their cal-
culation. Finally, we restrained our analysis to costs and
outcomes incurred over 1 year. Several studies have
assessed the long-term benefits of intensive care and
found that ICU was a reasonably good use of resources,
especially in low-risk patients, i.e. patients with lower dis-
ease severity and higher short-term survival [31, 56, 57].
The results presented here are based on longitudinal
trial data collected in a large sample of ARDS patients
treated in 29 different-sized ICUs, which improves exter-
nal validity. In addition, the 1-year follow-up period en-
abled us to capture on-going risk of death beyond the
typical “short-term” follow-up periods of similar studies.
Additionally, we are among the first to provide estimates
of societal costs following ARDS. The estimates pre-
sented in this paper, broken down in several patient
groups and care settings, will be of use to health eco-
nomic modellers requiring cost and utility estimates to
populate decision-analytical models [58].
Conclusions
Given the high costs and low health-related quality of life
identified, there is significant scope for further research
aimed at improving care in this in-need patient group.
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